title: Upregulation of anticoagulant proteins, protein S and tissue factor pathway inhibitor, in the mouse myocardium with cardio-specific TNF-α overexpression.
abstract: Heart failure (HF) has been recognized as a hypercoagulable state. However, the natural anticoagulation systems in the failing heart have not been studied. Recent experimental and clinical data have indicated that not only the thrombomodulin (TM)/protein C (PC) pathway but also the protein S (PS)/tissue factor pathway inhibitor (TFPI) system function as potent natural anticoagulants. To investigate the balance between procoagulant and anticoagulant activities in the failing heart, we measured the cardiac expression of tissue factor (TF), type 1 plasminogen activator inhibitor (PAI-1), TM, PC, PS, and TFPI by RT-PCR and/or Western blot analysis in male transgenic (TG) mice with heart-specific overexpression of TNF-α. Both procoagulant (TF and PAI-1) and anticoagulant (PS and TFPI) factors were upregulated in the myocardium of 24-wk-old TG (end-stage HF) but not in that of 4-wk-old TG (early decompensated HF) compared with the wild-type mice. Both factors were also upregulated in the infarcted myocardium at 3 days after coronary ligation in the wild-type mice. The expression of TM was downregulated in the TG heart, and PC was not detected in the hearts. The transcript levels of PS orphan receptors, Mer and Tyro3, but not Axl, were significantly upregulated in the TG heart. Double immunohistochemical staining revealed that myocardial infiltrating CD3-positive T cells may produce PS in the TG myocardium. In conclusion, the PS/TFPI was upregulated in the myocardium of a different etiological model of HF, thus suggesting a role for the PS/TFPI system in the protection of the failing heart under both inflammatory and hypercoagulable states.
authors.affiliation: Department of Cardiovascular and Geriatric medicine, Kyushu University Beppu Hospital, Japan. yhiguchi@beppu.kyushu-u.ac.jp
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Higuchi
authors.forename: Toru
authors.initials: T
authors.lastname: Kubota
authors.forename: Masamichi
authors.initials: M
authors.lastname: Koyanagi
authors.forename: Toyoki
authors.initials: T
authors.lastname: Maeda
authors.forename: Arthur M
authors.initials: AM
authors.lastname: Feldman
authors.forename: Naoki
authors.initials: N
authors.lastname: Makino
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D006333:Heart Failure / Q000378:metabolism*; D008074:Lipoproteins / Q000378:metabolism*; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D009206:Myocardium / Q000378:metabolism* / Q000473:pathology; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism; D011486:Protein C / Q000378:metabolism; D017293:Protein S / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism; D018180:Thrombomodulin / Q000378:metabolism; D013925:Thromboplastin / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics / Q000378:metabolism*; D015854:Up-Regulation / Q000502:physiology*
chemical_list: D008074:Lipoproteins; D017395:Plasminogen Activator Inhibitor 1; D011486:Protein C; D017293:Protein S; D012333:RNA, Messenger; D018180:Thrombomodulin; D014409:Tumor Necrosis Factor-alpha; C051928:lipoprotein-associated coagulation inhibitor; D013925:Thromboplastin